Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > From $0.52 to $28.00 in 12 months or $3.5 to $23 in 3 months

<< Previous

Bullboard Posts

Next >>

Comment by Azzak34on Jan 12, 2024 10:32am

167 Views

Post# 35823519

RE:RE:RE:From $0.52 to $28.00 in 12 months or $3.5 to $23 in 3 months

Unbuckable, the point is that some were saying that given our share price, we wouldn't see a significant rise or buyout. These examples show that isn't true. It's also an indication of what companies with lesser drugs are fetching in the market.

It's sad that we keep having to spell this out for you.

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism